Exploring Angiotensin II Receptor Blockers as a potential protective therapeutic for the Preclinical Stages of Alzheimer's Disease

Disease-modifying effects have been observed from monoclonal antibodies in symptomatic AD clinical trials. These are now being tested in Preclinical AD. ARBs may provide additional neuroprotective effects. It is also an appropriate option for those who don't have the economic or geographic means to receive monoclonal antibody infusions. With novel blood biomarkers for tau and Ab, Preclinical AD can be more easily diagnosed in the future. If this is the case, then perhaps prescribing an ARB preliminarily could slow any early pathological process occurring. In addition to a monoclonal antibody, the effects could be even more pronounced.